Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Polycystic Ovary Syndrome 2Pituitary Neoplasms 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Sarcoma 1Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neoplasms 1Obesity 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Liposarcoma 1Diabetes Mellitus, Type 2 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Temozolomide 64Radiotherapy 53Filgrastim 28Carboplatin 24Etoposide 20Irinotecan 17Vincristine 16Cyclophosphamide 16Cisplatin 15Carmustine 14Peripheral Blood Stem Cell Transplantation 13Magnetic Resonance Spectroscopy 12Bevacizumab 12Thiotepa 11Thalidomide 11Chemotherapy, Adjuvant 11Methotrexate 10Paclitaxel 9Granulocyte Colony-Stimulating Factor 9etoposide phosphate 8Surgical Procedures, Operative 8Procarbazine 8Ifosfamide 8sargramostim 7Topotecan 7O(6)-benzylguanine 7Lomustine 7Busulfan 7Radiation 6Melphalan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Central Nervous System Neoplasms × Rosiglitazone × Clear all
NCT00616642 2020-08-14

Rosiglitazone in Treating Patients With Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
1 enrolled 4 charts
CNSEndocrine

Pituitary Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡